Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IxCell hUC-MSC-S in recovery-phase ischemic stroke
NCT07197606Phase 2Not yet recruiting
- Sponsor
- iXCells Biotechnologies
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of IxCell in ischemic stroke, sponsored by iXCells Biotechnologies. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
IxCell
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07197606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197606.